An innovative screening technology that tags compounds with unique strands of DNA - like barcodes - will be used to assess up to a billion prototype drug molecules for anti-cancer activity, under a collaboration announced today (22 January 2014) between The Institute of Cancer Research, London, Cancer Research Technology (CRT) and Denmark-based drug discovery company Nuevolution A/S.
No comments:
Post a Comment